The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://allenzily864674.bloggactif.com/40264663/retatrutide-vs-tirzepatide-a-comparative-analysis